A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

This study tests a new oral drug called AP1189 — which works differently from standard rheumatoid arthritis medications — in people who have been recently diagnosed with RA and have never taken disease-modifying drugs (DMARDs). The goal is to find the right dose and see how well it reduces joint inflammation. **You may be eligible if...** - You have a confirmed diagnosis of rheumatoid arthritis - Your RA was diagnosed within the last 6 months and symptoms started no more than 18 months ago - You have not yet taken any DMARD medications - You have active joint inflammation (at least 6 tender and 6 swollen joints) and a high disease activity score - Your CRP (an inflammation marker in your blood) is elevated **You may NOT be eligible if...** - You have severe functional disability from RA - You have lupus, scleroderma, or another autoimmune disease in addition to RA - You have serious kidney, liver, or heart problems - You have gastrointestinal conditions affecting drug absorption - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.